Steve Brody


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Steve Brody is an accomplished trial lawyer who handles a wide variety of complex, aggregated litigation, with a primary focus on mass torts, product liability, class actions, government investigations, and appeals. Steve is Co-Chair of the firm's Product Liability and Mass Torts Practice, and leads the practice’s Drug and Medical Device subgroup. He also works frequently with attorneys in the firm’s Consumer Class Actions, White Collar Defense and Corporate Investigations, and Supreme Court and Appellate Practice Groups, and is Co-Chair of the firm’s Attorney General Investigations and Litigation Practice.

Steve works to advance clients’ business priorities through industry-shaping victories in high-profile litigation while simultaneously protecting clients’ financial and reputational interests with sophisticated media strategies, government and investor relations, and overall crisis management. Steve has defended mass torts, class actions and state attorney general cases involving pharmaceutical and medical device promotion, consumer fraud, false claims, state Medicaid reimbursement, health insurance plan benefits, and preferred provider agreements, among other issues. At the federal appellate level, he has recently handled appeals in the Fourth, Sixth, Seventh, Eighth, Ninth, Tenth, Eleventh and DC Circuits, and at the state level in Arkansas, California, Louisiana, Mississippi, Pennsylvania, New Jersey, South Carolina, Texas, Virginia, and West Virginia.


Honors & Awards

  • Recognized by Chambers USA for Product Liability & Mass Torts (2021)
  • Named a Life Sciences “Trailblazer” by The National Law Journal (2020)
  • Named a Litigation Star (2017-2018), Local Litigation Star (2017-2020), and National Practice Area Star (2019-2020) for Product Liability by Benchmark Litigation 
  • Recommended by The Legal 500 US for Dispute Resolution - Product Liability, Mass Tort and Class Action (2016-2021) and General Commercial Disputes (2020-2021)
  • “Life Sciences Star” for Products Liability Litigation and White-Collar/Government Investigations by LMG Life Sciences (2012-2020)
  • Washington DC Super Lawyer for Civil Litigation Defense (2013), Class Actions and Mass Torts (2014-2020)


Bar Admissions

  • District of Columbia
  • Virginia

Court Admissions

  • US District Court for District of Columbia
  • US Court of Appeals, District of Columbia, Fourth, Sixth, Seventh, Eighth, Ninth, and Tenth Circuits
  • US Supreme Court


  • Washington & Lee University, J.D., 1994 
  • Williams College, B.A., political economy, 1990

Professional Activities


  • International Association of Defense Counsel Mid-Year Meeting (2015); ABA Environmental, Mass Torts & Products Liability Litigation Committees’ Joint CLE Seminar (2015)
  • ACI Drug and Medical Device Conference (2014)
  • HarrisMartin’s Mass Tort Litigation Conference with Judge Marina Corodemus (Ret.) (2013, 2014)
  • PhRMA Law Section Annual Meeting (2013)
  • ACI 8th Advanced Summit on Off-Label Communications (2012)
  • ACI Expert Guide to Advertising, eMarketing & Promotions for the Pharmaceutical Industry (2011)
  • ACI 7th National Forum on Off-Label Communications (2010)
  • “Defense Perspectives on Attorney General Pharmaceutical Claims,” LexisNexis/HB Litigation Conferences (2008, 2009)
  • “Ethics & Discovery,” Practising Law Institute (2007, 2009-2015 (Chair))
  • In a seven-week televised trial garnering national media attention, defended against the State of Oklahoma’s claims in the first case to go to trial against an opioid manufacturer 
  • Obtained appellate reversal and dismissal of US$1.2 billion Medicaid fraud judgment against pharmaceutical manufacturer in action brought by the Arkansas Attorney General 
  • Prevailed on appeal from $330 million judgment in Medicaid fraud action by the Louisiana Attorney General, winning reversal and entry of judgment in favor of pharmaceutical 
  • Defended a US$74 million constructive fraudulent conveyance action for a hospital and health systems operator in the US Bankruptcy Court for the District of Columbia in a seven-week bench trial, securing a full defense judgment on all claims that was upheld on appeal to the district court 
  • Obtained reversal of US$4.5 million consumer fraud judgment against a pharmaceutical manufacturer in a state court action brought by the West Virginia Attorney General